Zanamivir Patent Expiration
Zanamivir is Used for preventing influenza. It was first introduced by Glaxosmithkline
Zanamivir Patents
Given below is the list of patents protecting Zanamivir, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Relenza | US6294572 | Crystalline N-acetyl neuraminic acid derivatives and process for their preparation |
Dec 15, 2014
(Expired) | Glaxosmithkline |
| Relenza | US5648379 | Derivatives and analogues of 2-deoxy-2,3-didehydro-n-acetyl neuraminic acid and their use as antiviral agents |
Jul 15, 2014
(Expired) | Glaxosmithkline |
| Relenza | US5360817 | Derivatives and analogues of 2-deoxy-2,3-didehydro-N-acetyl neuraminic acid and their use as antiviral agents |
Jul 26, 2013
(Expired) | Glaxosmithkline |
Zanamivir's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Zanamivir:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| An Intravenous (IV) Zanamivir Pharmacokinetics (PK) Study in Hospitalized Neonates and Infants With Influenza Infection | GlaxoSmithKline | NA |
COMPLETED
(Jul 1, 2026)
| PHASE2 |
| Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE) | George Washington University | NA |
RECRUITING
(Jul 1, 2026)
| PHASE2 |